Vor Biopharma (VOR) Free Cash Flow (2020 - 2026)

Vor Biopharma (VOR) has reported Free Cash Flow for 7 consecutive years, with -$38.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 23.27% year-over-year to -$38.3 million; the TTM figure through Mar 2026 stood at -$150.9 million (down 50.32% YoY), while the FY2025 annual figure was -$143.7 million, down 43.81% from the prior year.
• Free Cash Flow slipped to -$38.3 million in Q1 2026 per VOR's latest filing, from -$23.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$11.1 million in Q3 2022 and bottomed at -$53.9 million in Q3 2025.
• Historically, Free Cash Flow has averaged -$27.5 million across 5 years, with a median of -$24.6 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 44.22% — and 2023, when it sank 155.18%.
• Vor Biopharma's Free Cash Flow stood at -$18.3 million in 2022, then dropped by 26.24% to -$23.1 million in 2023, then retreated by 4.31% to -$24.1 million in 2024, then gained by 4.23% to -$23.1 million in 2025, then slumped by 65.67% to -$38.3 million in 2026.
• Business Quant data shows VOR's Free Cash Flow at -$38.3 million in Q1 2026, -$23.1 million in Q4 2025, and -$53.9 million in Q3 2025.